Developing a PCR test for Fusobacterium in tumor patients
Developing a Real-Time PCR Assay for Fusobacterium and Epidemiological Analysis of Tumor Patients
This study is testing a new way to check for Fusobacterium bacteria in stool samples from tumor patients to see how it might relate to their diagnosis and treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 490 (estimated) |
| Sex | All |
| Sponsor | Zhujiang Hospital Academic / other |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT06168513 on ClinicalTrials.gov |
What this trial studies
This study focuses on creating a fluorescence quantitative PCR detection method to accurately measure the presence of Fusobacterium species in human fecal samples. It aims to analyze the prevalence of these bacteria in patients with tumors and explore potential correlations between Fusobacterium presence and various diagnostic and prognostic indicators. By classifying Fusobacterium accurately, the study seeks to enhance understanding of its role in tumor development and improve clinical practices related to tumor diagnosis and treatment.
Who should consider this trial
Good fit: Ideal candidates include patients with a documented history of tumors who have provided fecal samples at the participating hospital.
Not a fit: Patients who have taken antimicrobial preparations in the past three months or those with incomplete sample information may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic methods and better understanding of the relationship between Fusobacterium and tumor development.
How similar studies have performed: While the approach of using PCR for bacterial detection is established, the specific focus on Fusobacterium in tumor patients is relatively novel and not extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * The inclusion criteria for this study encompassed fecal specimens obtained from patients with a documented history of tumor, specifically those who received their primary or initial tumor diagnosis at our hospital. * Inclusion criteria for the control group consisted of the following: (1) Individuals who were in good health, devoid of evident diseases, and possessed normal physical examination reports; (2) Individuals who had not experienced significant chronic illnesses, such as hypertension, diabetes, chronic kidney disease, etc., in recent years, in order to exclude those who had been unwell but had normal physical examination reports; (3) Age and gender were matched with the case group. Exclusion Criteria: The exclusion criteria for this study include: A) Individuals who have taken an antimicrobial preparation within the past three months. B) Samples that lack complete information and cannot be traced back to their source. C) Samples with an insufficient volume for detection. D) Samples that do not meet the requirements for sample collection and preservation. -
Where this trial is running
Guangzhou, Guangdong
- Zhujiang Hospital of Southern Medical University — Guangzhou, Guangdong, China (Recruiting)
Study contacts
- Study coordinator: Tingting Shen
- Email: 517184185@qq.com
- Phone: 15521240170
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.